Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6675917 | 0.81 | CHRNB4 (0.39) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL14322211 | 0.78 | NISCH (0.32) | — | |
| SCHEMBL3472201 | 0.78 | — | — | |
| SCHEMBL20563076 | 0.77 | — | — | |
| SCHEMBL9685921 | 0.75 | CHRNB4 (0.49) | CHRNB4CHRNA3CHRNB2CHRNA4POLB | |
| SCHEMBL76420 | 0.75 | CD274 (0.32) | — | |
| SCHEMBL7337428 | 0.75 | POLB (0.38) | POLBESR2 | |
| SCHEMBL8347684 | 0.74 | NISCH (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4POLB | |
| SCHEMBL2884153 | 0.74 | — | — | |
| SCHEMBL266615 | 0.74 | NISCH (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1811991-B1 | Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis | GENZYME CORP (US) | 2018-11-07 | — | — | EP | claimed |
| US-7803827-B2 | 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents; 1-(aminosulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(3,4-dimethylphenyl)-2-imidazolidinone | WYETH LLC (US) | 2010-09-28 | — | — | US | claimed |
| EP-1855696-B1 | 9A-CARBAMOYL-Y-AMINOPROPYL- AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL-AZALIDES WITH ANTIMALARIAL ACTIVITY | GLAXOSMITHKLINE ZAGREB (HR) | 2010-04-28 | — | — | EP | claimed |
| EP-2035392-A1 | IMIDAZOLE KV1. 5 POTASSIUM CHANNEL INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-03-18 | — | — | EP | claimed |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2009-03-12 | — | — | US | claimed |
| US-20080200404-A1 | Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2008-08-21 | — | — | US | claimed |
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | claimed |
| WO-2007149874-A1 | IMIDAZOLIDINONE KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | WO | claimed |
| EP-1855696-A2 | 9A-CARBAMOYL-Y-AMINOPROPYL- AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL-AZALIDES WITH ANTIMALARIAL ACTIVITY | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2007-11-21 | — | — | EP | claimed |
| WO-2006085228-A2 | 9A-CARBAMOYL-Y-AMINOPROPYL AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL-AZALIDES WITH ANTIMALARIAL ACTIVITY | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (GB) | 2006-08-17 | — | — | WO | claimed |
| US-20060089503-A1 | Processes for producing optically active 2-thiomethyl-3-phenylpropionic acid derivative and for producing intermediate therefor | KANEKA CORPORATION (JP) | 2006-04-27 | — | — | US | claimed |
| EP-1577310-A1 | PROCESSES FOR PRODUCING OPTICALLY ACTIVE 2-THIOMETHYL-3-PHENYLPROPIONIC ACID DERIVATIVE AND FOR PRODUCING INTERMEDIATE THEREFOR | KANEKA CORPORATION (JP) | 2005-09-21 | — | — | EP | claimed |
| US-6403633-B2 | USEFUL ANTIANGIOGENIC, ANTIARTHRITIC, ANTIINFLAMMATORY, ANTIRESTENOTIC, ANTIINVASIVE, ANTIMETASTIC, ANTIOSTEOPOROTIC, ANTIRETINOPATHIC, CONTRACEPTIVE AND TUMORISTATIC TREATMENT AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | claimed |
| US-6355634-B1 | OXIME DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-12 | — | — | US | claimed |
| EP-1811991-B1 | Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis | GENZYME CORP (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-2923699-B1 | METHODS OF TREATING FATTY LIVER DISEASE COMPRISING INHIBITING GLUCOSPHINGOLIPID SYNTHESIS | GENZYME CORP (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20170281593-A1 | Methods of Treating Fatty Liver Disease | GENZYME CORPORATION | 2017-10-05 | — | — | US | disclosed |
| US-5677322-A | THERAPY FOR AGING, DIABETES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| EP-0638075-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994019335-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281593-A1 | Methods of Treating Fatty Liver Disease | LIPC, GYS2, PNLIP | CHRNB4 4010/4885CHRNA3 3403/4885CHRNB2 3660/4885 |
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNK5, KCNH2 | CHRNB4 748/4885CHRNA3 438/4885CHRNB2 741/4885 |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNK5, KCNH2 | CHRNB4 748/4885CHRNA3 438/4885CHRNB2 741/4885 |
| US-20080200404-A1 | Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides | DCTD, DHODH, DHRS9 | CHRNB4 4444/4885CHRNA3 3766/4885CHRNB2 4565/4885 |
| US-20060089503-A1 | Processes for producing optically active 2-thiomethyl-3-phenylpropionic acid derivative and for producing intermediate therefor | NOTUM, FAR1, ALDH7A1 | CHRNB4 4565/4885CHRNA3 4583/4885CHRNB2 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.